Avadel Pharmaceuticals Plc Sponsored ADR AVDL 深 沪
等待开盘 12-19 09:30:00 美东时间
21.42
+0.020
+0.09%
华盛通- 最 高21.455
- 今 开21.42
- 成交量 138.72万股
- 最 低 21.38
- 昨 收 21.40
- 总市值 21.02亿
- 52周最高 23.57
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.38
- 委 比 34.60%
- 总股本 9814.11万
- 历史最高 23.57
- 量 比 1.18
- 振 幅 0.35%
- 历史最低 1.03
- 每 手 1
- 风险率 4.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
Avadel Pharmaceuticals completed patient enrollment in the Phase 3 REVITALYZ trial evaluating LUMRYZ as a potential treatment for idiopathic hypersomnia (IH). The trial aims to assess LUMRYZ's efficacy and safety as a once-at-bedtime treatment for IH, targeting excessive daytime sleepiness and sleep inertia. LUMRYZ, an extended-release sodium oxybate, has shown benefits for narcolepsy patients and holds potential for IH if approved. Data expected...
12-18 12:00
Avadel Pharmaceuticals Acquisition Moves Forward with HSR Expiry
Avadel Pharmaceuticals ( ($AVDL) ) has issued an update. On December 8, 2025, t...
12-10 05:52
Alkermes To Acquire Avadel Pharmaceuticals In Shareholder Scheme, Sends Proposal To Equity And Employee Share Purchase Plan Holders
As previously announced, the board of directors of Avadel Pharmaceuticals plc (NASDAQ:AVDL), a public limited company incorporated in Ireland (the "Company" or "Avadel") and the board of directors of Alkermes plc
12-06 05:03
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
Avadel Pharmaceuticals and Alkermes have agreed to terms for Alkermes to acquire Avadel through a scheme of arrangement under Irish law. The Irish High Court has approved the plan, and a shareholder meeting will be held on January 12, 2026, to vote on the transaction. A proxy statement outlining the terms and conditions of the proposed transaction has been mailed to shareholders.
12-01 21:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Wells Fargo Maintains Equal-Weight on Avadel Pharmaceuticals, Raises Price Target to $22.5
Wells Fargo analyst Benjamin Burnett maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Equal-Weight and raises the price target from $20 to $22.5.
11-20 23:42
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid
Alkermes (ALKS) has raised its buyout offer for Avadel Pharmaceuticals (AVDL), indicating a price of up to $22.50 per share for the deal, the companies announced on Wednesday after the Irish biotech’s...
11-19 20:00
Avadel Pharmaceuticals Amends Agreement with Alkermes
Avadel Pharmaceuticals ( ($AVDL) ) has issued an announcement. On November 18, ...
11-19 19:48
Alkermes Increases Offer for Avadel Acquisition
Alkermes ( ($ALKS) ) has shared an announcement. On November 18, 2025, Alkermes...
11-19 19:47
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH J...
11-19 19:00
